Bicalutamide: Primary Indication and Use
Bicalutamide is a nonsteroidal antiandrogen (androgen receptor inhibitor) used primarily in combination with LHRH agonists (like leuprolide or goserelin) to treat Stage D2 metastatic prostate cancer 1.
FDA-Approved Indications
The FDA-approved use is specifically:
- Bicalutamide 50 mg daily in combination with an LHRH analog for Stage D2 metastatic prostate cancer 1
- Bicalutamide 150 mg daily is NOT approved for use alone or with other treatments 1
Mechanism of Action
Bicalutamide works by competitively blocking androgen receptors in target tissues, preventing testosterone and dihydrotestosterone from binding 2. Unlike LHRH agonists that lower testosterone production, bicalutamide blocks the action of androgens at the receptor level while testosterone levels actually rise during treatment 2.
Clinical Use Patterns
Metastatic Prostate Cancer (Standard Use)
- Combined androgen blockade (CAB): Bicalutamide 50 mg daily + LHRH agonist shows equivalent or potentially superior outcomes compared to castration alone 3
- Meta-analyses demonstrate a small but statistically significant survival benefit when adding nonsteroidal antiandrogens to castration therapy (HR 0.92, p=0.005) 3
- Bicalutamide has a convenient once-daily dosing schedule due to its approximately 1-week half-life 2
Locally Advanced Disease
When used at 150 mg daily (off-label in many contexts):
- Improves progression-free survival in locally advanced prostate cancer when added to radiotherapy 4, 5
- ESMO guidelines suggest bicalutamide 150 mg daily can be considered as an alternative to LHRH agonists for adjuvant therapy in men who prioritize sexual function preservation 5
- The Early Prostate Cancer trial showed benefit in locally advanced disease but NOT in localized disease 4, 6
Important Caveat for Localized Disease
Do not use bicalutamide 150 mg for localized prostate cancer - studies show no benefit and a potential survival trend favoring placebo in watchful waiting patients 4, 6.
Quality of Life Considerations
Bicalutamide offers distinct advantages over castration:
- Preserved sexual function: Patients maintain higher testosterone levels and report better sexual interest and physical capacity compared to medical/surgical castration 2
- Lower incidence of hot flashes compared to castration (though still occurs in ~20-32% of patients) 3
- Trade-off: High rates of gynecomastia (69%) and breast pain (74%) 6, 7
Critical Safety Warnings
Hepatotoxicity
- Severe liver injury, including fatal hepatic failure, has been reported 1
- Monitor liver function tests before starting and regularly during treatment 1
- While most hepatotoxicity occurs early, delayed onset (up to 5 months) has been documented 8
Other Important Warnings
- Increased bleeding risk when combined with warfarin - monitor INR closely 1
- May affect glucose tolerance in diabetic patients 1
- Causes somnolence - caution with driving/operating machinery 1
- Photosensitivity - use sunscreen 1
Comparison to Newer Agents
Enzalutamide has largely superseded bicalutamide in many clinical scenarios:
- TERRAIN and STRIVE trials showed enzalutamide significantly superior to bicalutamide 50 mg for metastatic CRPC (HR 0.44 and 0.24 respectively) 9, 10
- However, bicalutamide remains a reasonable option given different side-effect profiles and substantially lower cost 9, 10
Practical Dosing
- 50 mg once daily when combined with LHRH agonist (standard FDA-approved dose)
- Start bicalutamide simultaneously with LHRH agonist to prevent testosterone flare 1
- Can be taken with or without food, morning or evening (but same time daily) 1
- 150 mg once daily for monotherapy in locally advanced disease (off-label in US, but supported by guidelines for specific populations) 5